172 Transforming the National Genomic Test Directory to Improve Genomic Testing for CNS Tumours

Clicks: 14
ID: 326793
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #268 of 287 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 287 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction The National Genomic Test Directory (NGTD), introduced in 2019, defines NHS commissioned genomic tests in England and outlines their clinical eligibility. In cancers of the central nervous system (CNS), neuropathologists routinely integrate genomic analysis into diagnostic workflows to support tumour classification and clinical patient management. However, the existing Excel based NGTD is difficult to navigate and lacks the flexibility required, highlighting the need for a modernised, digital alternative. Methods The NHS England (NHSE) Genomics Unit undertook extensive stakeholder engagement to define the requirements for a digital directory. Test Directory content was evaluated alongside Patient Level Contract Monitoring data to identify requesting patterns, redundancy and evolving clinical needs. The WHO Blue Book on CNS Tumours was reviewed with adult and paediatric neuropathology experts to determine diagnostic genomic testing requirements, and relevant precision medicine genomic targets. The Digital Genomic Test Directory Service (DGTS) was developed as the platform to deliver the NGTD and support transformation of genomic testing for CNS tumours. Results Stakeholder input and data review demonstrated the need to update and restructure the NGTD in alignment with WHO classifications. A differential diagnostic approach was adopted, incorporating broader NGS panels that support integrated diagnosis while retaining targeted assays for urgent or salvage testing. Redundant tests identified through analysis were removed. Phase 1 of the programme has been completed, consolidating CNS tumour indications from 58 indications into seven streamlined test packages. Conclusions NHSE has initiated a major transformation to deliver the NGTD in a fully digital format via the DGTS, improving access to commissioned genomic tests essential for CNS tumour diagnosis and management. CNS tumours represent the first transformed disease area, setting the foundation for broader digital transformation across solid cancers.
Reference Key
openalex_W7204476234 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jane Starczynski, Maricica Zabrautanu, Peter Street, Thomas Jacques, Kathreena Kurian, Ross Finnegan
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.045
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.045/70805959/noag172.045.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.